Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs.
A prospective study of 120 patients with cancer was carried out to evaluate the effects of potentially cardiotoxic anticancer drugs using radionuclide cardiovascular studies. Five groups were studied: 7 patients received 4'-demethoxydaunorubicin, 23 4'-deoxydoxorubicin, 34 4'-epidoxorubicin, 49 mitoxantrone and 7 4'-(9-acridinylamino)-methan-sulphon-m-anisidide (amsa). Two patients receiving 4'-demethoxydaunorubicin, 7 on 4'-deoxydoxorubicin, 11 on 4'-epidoxorubicin, 21 on mitoxantrone and 3 on amsa had falls of greater than or equal to 10% in their left ventricular ejection fraction. Using data from this study, the recommended guidelines are set out.
Vorobiof
D A
DA
Department of Medical Oncology, University of Pretoria.
Falkson
G
G
Iturralde
M P
MP
D000677:Amsacrine / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004562:Electrocardiography; D015251:Epirubicin; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging* / Q000503:physiopathology; D006801:Humans; D015255:Idarubicin; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D011446:Prospective Studies; D011875:Radionuclide Angiography; D013318:Stroke Volume / Q000187:drug effects
D000903:Antibiotics, Antineoplastic; D000677:Amsacrine; D015251:Epirubicin; D004317:Doxorubicin; D008942:Mitoxantrone; C030851:esorubicin; D015255:Idarubicin; D003630:Daunorubicin